☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
expand
Verily Acquires SignalPath to Expand its Clinical Research Capabilities
August 18, 2021
Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline
March 31, 2021
Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar- adalimumab) in Australia and Canada
March 30, 2021
Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities
March 26, 2021
mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity
March 23, 2021
Pfizer's Lorbrena (lorlatinib) Receives FDA's Approval for Expanding its Indication to Treat ALK-Positive Metastatic Lung Cancer
March 4, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.